natgillin/translations-raw huggingface dataset:
In the majority of patients with urea cycle disorders or haemoglobinopathies receiving various doses of phenylbutyrate (300 - 650 mg/kg/day up to 20 g/day) no plasma level of phenylacetate could be detected after overnight fasting.
Pri večini bolnikov z motnjami ciklusa sečnine ali hemoglobinopatijami, ki so prejemali različne odmerke fenilbutirata (300 – 650 mg/kg/dan do 20 g/dan) ni bilo moč zaznati plazemskih koncentracij fenilacetata po prekonočnem postu.
In the majority of patients with urea cycle disorders or haemoglobinopathies receiving various doses of phenylbutyrate (300 - 650 mg/kg/day up to 20 g/day) no plasma level of phenylacetate could be detected after overnight fasting.
Pri večini bolnikov z motnjami ciklusa sečnine ali hemoglobinopatijami, ki so prejemali različne odmerke fenilbutirata (300–650 mg/kg/dan do 20 g/dan), ni bilo moč zaznati plazemskih koncentracij fenilacetata po prekonočnem postu.
In the majority of the occasions the necessary amount of Avastin can be diluted with 0.9 % sodium chloride solution for injection to a total volume of 100 mL.
V večini primerov lahko potrebno količino zdravila Avastin razredčimo z 0,9-% raztopino natrijevega klorida za injiciranje do končnega volumna 100 ml.
In the majority of these cases, MabThera was administered with chemotherapy.
V večini teh primerov so zdravilo MabThera uporabili skupaj s kemoterapijo.
In the majority of these patients the elevations were generally mild, and remained below two times the upper limit of normal range
Pri večini teh bolnikov je bilo povečanje navadno blago in ni preseglo dvakratne koncentracije zgornje meje normalne vrednosti.
In the majority of these patients the elevations were generally mild, and remained below two times the upper limit of normal range.
Pri večini teh bolnikov je bilo povišanje navadno blago in ni preseglo dvakratne koncentracije zgornje meje normalne vrednosti
In the male and female rat, following intravenous administration, Lutetium (177Lu) chloride is rapidly cleared from the blood: at 5 min post injection, only 1.52% of the injected activity (%ID) is found in blood (corresponding to 0.08%ID/g) and no activity above background levels remains 1 hour post dose.
Pri podganjih samcih in samicah se lutecijev (177Lu) klorid po intravenskem dajanju hitro izloči iz krvi: 5 minut po injiciranju je v krvi najdene le 1,52 % injicirane aktivnosti (% ID) (kar ustreza 0,08 % ID/g), eno uro po odmerku pa ni nobene aktivnosti, ki bi presegala izhodiščne ravni.
In the male dog, after one year of dosing, reversible bile plugs in canaliculi were observed at exposures greater than 1.9 fold the human exposure.
Po enem letu odmerjanja pri pasjih samcih so opazili reverzibilne zamašitve izvodil žolča pri izpostavljenostih, višjih od 1,9-kratne izpostavljenosti pri ljudeh.
In the management of overdose with any medicinal product, it should be borne in mind that multiple agents may have been taken.
Pri obravnavanju prevelikega odmerka kakršnegakoli zdravila je treba pomisliti na možnost, da je oseba zaužila različna zdravila.
in the maximum PR interval
PR intervala.
In the mBCC cohort, tumour response was assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.0. In the laBCC cohort, tumour response was assessed based on visual assessment of external tumour and ulceration, tumour imaging (where appropriate), and tumour biopsy.
V kohorti z metastatskim bazalnoceličnim karcinomom so odziv tumorja ocenjevali po merilih RECIST (Response Evaluation Criteria in Solid Tumours), verzija 1.0. V kohorti z lokalno napredovalim bazalnoceličnim karcinomom so odziv tumorja ocenjevali na podlagi vizualne ocene zunanjega tumorja in ulceracij, slikanja tumorja (kjer je bilo to ustrezno) in biopsije tumorja.
In the MCL Clinical Trial, a Phase 3 clinical trial for mantle cell lymphoma, 11% of patients reported hyperglycaemia as an adverse event.
V kliničnem preskušanju MCL, kliničnem preskušanju 3. faze pri limfomu plaščnih celic, je 11 % bolnikov poročalo o hiperglikemiji kot neželenem učinku.
In the MCL Clinical Trial, hyperlipaemia was reported as an adverse event in 9.3% of patients.
V kliničnem preskušanju MCL so poročali o hiperlipemiji kot neželenem učinku pri 9,3 % bolnikov.
In the MCL Clinical Trial, there was no difference in efficacy in patients with respect to age, sex, race, geographic region, or baseline disease characteristics.
V kliničnem preskušanju MCL ni bilo razlik v učinkovitosti pri bolnikih glede na starost, spol, raso, zemljepisno območje ali izhodiščne značilnosti bolezni.
In the mid-gut of susceptible insect species, the insect’s enzymes remove the carbomethoxy group from parent indoxacarb, and convert it into its biologically active form.
V črevesju občutljivih vrst insektov encimi odstranijo karbometoksi skupino iz indoksakarba in ga pretvorijo v biološko aktivno obliko.
In the middle of the cycle (Week Two/Day 8 or Week Three/Day 15) for one or two days (up to 48 hours): The user should apply a new EVRA transdermal patch immediately.
V sredini cikla (2. teden/8. dan ali 3. teden/15. dan) en ali dva dni (do 48 ur): Ženska mora takoj namestiti nov transdermalni obliž EVRA.
In the middle of your patch cycle (Week 2 or 3):
redi cikla (2. ali 3. teden):
In the morning, take 600 milligram PREZISTA together with 100 milligram ritonavir.
Zjutraj vzemite 600 miligramov zdravila PREZISTA skupaj s 100 miligrami ritonavirja.
In the morning, take one 600 milligram PREZISTA tablet together with 100 milligram ritonavir.
Zjutraj vzemite eno 600-miligramsko tableto zdravila PREZISTA skupaj s 100 miligrami ritonavirja.
In the morning, take two 300 milligram PREZISTA tablets together with 100 milligram ritonavir.
Zjutraj vzemite dve 300-miligramski tableti PREZISTA skupaj s 100 miligrami ritonavirja.
in the morning, with food
UPORABL JENO Z
In the most extreme case of overdose, the patient survived the oral intake of a total of 2,000 mg memantine with effects on the central nervous system (coma for 10days, and later diplopia and agitation).
V najekstremnejšem primeru prevelikega odmerjanja je bolnik preživel peroralni vnos 2000 mg memantina z učinki na centralni živčni sistem (desetdnevna koma, kasneje diplopija in vznemirjenost).
In the most extreme case of overdose, the patient survived the oral intake of a total of 2000mg memantine with effects on the central nervous system (coma for 10 days, and later diplopia and agitation).
V najekstremnejšem primeru prevelikega odmerjanja je bolnik preživel peroralni vnos 2000 mg memantina z učinki na osrednji živčni sistem (desetdnevna koma, kasneje diplopija in vznemirjenost).
In the most recent clinical study in which 123 patients were administered Scintimun, the most commonly reported adverse reaction was the development of anti-mouse antibodies (HAMA) in 14 % of the patients, after a single administration (16 positive over 116 assayed one and/or three months after the administration).
V večini nedavnih kliničnih študij, v katerih je 123 preiskovancev prejelo zdravilo Scintimun, je bila najpogosteje ugotovljen neželeni učinek nastanek humanih protiteles proti mišjim protitelesom (HAMA) pri 14 % preiskovancev po eni uporabi (16 pozitivnih od 116 testiranih en in/ali tri mesece po uporabi zdravila).
In the MRI cohort 36% of patients entering the study had Gd+ lesions at baseline (mean number of Gd+ lesions 1.4).
V kohorti MRS je imelo 36 % bolnikov, ki so vstopali v študijo, lezije Gd+ ob izhodišču (povprečno število lezij Gd+ 1,4).
In the MRI cohort 45% of patients entering the study had Gd+ lesions at baseline (mean number of Gd+ lesions 2.4).
V kohorti MRS je imelo 45 % bolnikov, ki so vstopali v študijo, lezije Gd+ ob izhodišču (povprečno število lezij Gd+ 2,4).
In the multicentre, open-label, single arm VIKING-3 study (ING112574), HIV-1 infected, ART-experienced adults with virological failure and current or historical evidence of raltegravir and/or elvitegravir resistance received Tivicay 50 mg twice daily with the current failing background regimen for 7 days but with optimised background ART from Day 8.
V multicentrični, odprti študiji VIKING-3 (ING112574) je ena skupina odraslih, okuženih z virusom HIV-1, ki so že prejemali ART in so bili brez virološkega odziva ter so bili bodisi takrat ali v preteklosti odporni na raltegravir in/ali elvitegravir, prejemala 50 mg zdravila Tivicay dvakrat na dan, ob trenutno neuspešni osnovni shemi 7 dni, vendar ob optimiziranem osnovnem zdravljenju z ART od 8. dneva dalje.
In the multinational 2NN study with Viramune immediate-release, a population pharmacokinetic substudy of 1,077 patients was performed that included 391 females.
V sklopu večdržavne študije 2NN z zdravilom Viramune s takojšnim sproščanjem so izvedli populacijsko farmakokinetično podštudijo, ki je zajela 1077 bolnikov, od tega 391 žensk.
In the natural setting, i.e., with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis.
Ob spolnem vzburjenju poveča dotok krvi v penis in tako izboljša oslabljeno erektilno funkcijo.
In the neoadjuvant setting (NEOSPHERE) the incidence of LVD was higher in the Perjeta–treated groups than in those who did not receive Perjeta.
Pri neoadjuvatnem zdravljenju (NEOSPHERE) je bila incidenca LVD večja v skupinah, zdravljenih z zdravilom Perjeta, kot pri tistih, ki zdravila Perjeta niso prejemali.
In the neoadjuvant setting, locally advanced and inflammatory breast cancers are considered as high- risk irrespective of hormone receptor status.
V okviru neoadjuvantnega zdravljenja smatramo lokalno napredovali in vnetni rak dojk kot visoko tvegana, neodvisno od statusa hormonskih receptorjev.
In the neoadjuvant setting, the experience of concurrent administration of Herceptin and low dose anthracycline regimen is limited (see section 4.4).
Pri neoadjuvantnem zdravljenju je izkušenj z dajanjem zdravila Herceptin sočasno s shemami, ki vsebujejo majhne odmerke antraciklinov, malo (glejte poglavje 4.4).
In the neoadjuvant trial NEOSPHERE , in which patients received 4 cycles of Perjeta as neoadjuvant treatment, the incidence of LVD (during the overall treatment period) was higher in the Perjeta, trastuzumab and docetaxel-treated group (7.5%) compared to the trastuzumab and docetaxel-treated group (1.9%).
V preskušanju neoadjuvantnega zdravljenja NEOSPHERE, v katerem so bolniki za neoadjuvantno zdravljenje prejeli 4 cikle zdravila Perjeta, je bila incidenca LVD (tekom celotnega obdobja zdravljenja) večja v skupini, zdravljeni z zdravilom Perjeta, trastuzumabom in docetakselom (7,5 %), v primerjavi s skupino, zdravljeno s trastuzumabom in docetakselom (1,9 %).
In the neoadjuvant trial NEOSPHERE, the most common ADRs (≥50%) seen with Perjeta in combination with trastuzumab and docetaxel were alopecia and neutropenia.
V preskušanju neoadjuvantnega zdravljenja NEOSPHERE sta bila najpogostejša neželena učinka (≥ 50 %), opažena pri zdravljenju z zdravilom Perjeta v kombinaciji z trastuzumabom in docetakselom, alopecija in nevtropenija.
In the neoadjuvant trial TRYPHAENA, the incidence of LVD (during the overall treatment period) was 8.3% in the group treated with Perjeta plus trastuzumab and FEC (followed by Perjeta plus trastuzumab and docetaxel); 9.3% in the group treated with Perjeta plus trastuzumab and docetaxel following FEC; and 6.6% in the group treated with Perjeta in combination with TCH.
V preskušanju neoadjuvantnega zdravljenja TRYPHAENA je bila incidenca LVD (tekom celotnega obdobja zdravljenja) 8,3 % v skupini, ki je po zdravljenju z zdravilom Perjeta, trastuzumabom in shemo FEC prejela zdravilo Perjeta, trastuzumab in docetaksel; 9,3 % v skupini, ki je po zdravljenju s shemo FEC prejela zdravilo Perjeta, trastuzumab in docetaksel; in 6,6 % v skupini, zdravljeni z zdravilom Perjeta v kombinaciji s shemo TCH.
In the neoadjuvant trial TRYPHAENA, when Perjeta was administered in combination with trastuzumab and FEC (5-fluorouracil, epirubicin, cyclophosphamide) for 3 cycles followed by 3 cycles of Perjeta, trastuzumab and docetaxel, the most common ADRs (≥50%) were neutropenia, diarrhoea and nausea.
V preskušanju neoadjuvantnega zdravljenja TRYPHAENA, ko so zdravilo Perjeta uporabili v kombinaciji s trastuzumabom in shemo FEC (5-fluorouracil, epirubicin, ciklofosfamid) v 3 ciklih, ki so jim sledili 3 cikli zdravila Perjeta, trastuzumaba in docetaksela, so bili najpogostejši neželeni učinki (≥ 50 %) nevtropenija, diareja in navzea.
In the neoadjuvant-adjuvant EBC treatment setting, 8.1 % (24/296) of patients treated with Herceptin intravenous and 14.9 % (44/295) of patients receiving Herceptin subcutaneous vial developed antibodies against trastuzumab (regardless of antibody presence at baseline).
Pri neoadjuvantnem-adjuvantnem zdravljenju zgodnjega raka dojk so se pri 8,1 % bolnikov (24/296), zdravljenih z intravensko obliko zdravila Herceptin, in 14,9 % bolnikov (44/295), ki so prejemali subkutano obliko zdravila Herceptin v viali, razvila protitelesa proti trastuzumabu (ne glede na prisotnost protiteles pred zdravljenjem).
In the neoadjuvant-adjuvant EBC treatment setting, 8.1 % (24/296) of patients treated with Herceptin intravenous developed antibodies against trastuzumab (regardless of antibody presence at baseline).
Pri neoadjuvantnem-adjuvantnem zdravljenju zgodnjega raka dojk so se pri 8,1 % bolnikov (24/296), zdravljenih z intravensko obliko zdravila Herceptin, razvila protitelesa proti trastuzumabu (ne glede na prisotnost protiteles pred zdravljenjem).
In the NEOSPHERE and TRYPHAENA trials in the neoadjuvant setting, Perjeta was administered on the same day as the other study treatment drugs in all cycles.
V preskušanjih neoadjuvantnega zdravljenja NEOSPHERE in TRYPHAENA so zdravilo Perjeta dajali isti dan kot druga študijska zdravila v vseh ciklih.
In the NEOSPHERE trial, 8.4% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel experienced febrile neutropenia compared with 7.5% of patients treated with trastuzumab and docetaxel.
V preskušanju NEOSPHERE se je pri 8,4 % bolnikov, ki so prejeli neoadjuvantno zdravljenje z zdravilom Perjeta, trastuzumabom in docetakselom, pojavila febrilna nevtropenija, v primerjavi s 7,5 % bolnikov, ki so se zdravili s trastuzumabom in docetakselom.
In the NEOSPHERE trial, diarrhoea occurred in 45.8% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel compared with 33.6% of patients treated with trastuzumab and docetaxel.
V preskušanju NEOSPHERE se je diareja pojavila pri 45,8 % bolnikov, ki so se neoadjuvantno zdravili z zdravilom Perjeta, trastuzumabom in docetakselom, v primerjavi s 33,6 % bolnikov, ki so se zdravili s trastuzumabom in docetakselom.
In the NEOSPHERE trial, rash occurred in 40.2% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel compared with 29.0% of patients treated with trastuzumab and docetaxel.
V preskušanju NEOSPHERE se je izpuščaj pojavil pri 40,2 % bolnikov, ki so se neoadjuvantno zdravili z zdravilom Perjeta, trastuzumabom in docetakselom, v primerjavi z 29,0 % bolnikov, ki so se zdravili s trastuzumabom in docetakselom.
In the NEOSPHERE trial, the incidence of NCI-CTCAE v.3 Grade 3-4 neutropenia was 74.5% in patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel compared with 84.5% in patients treated with trastuzumab and docetaxel, including 50.9% and 60.2% Grade 4 neutropenia, respectively.
V preskušanju NEOSPHERE je bila incidenca nevtropenije stopnje 3–4 po merilih NCI-CTCAE (različica 3) 74,5 % pri bolnikih, ki so se neoadjuvantno zdravili z zdravilom Perjeta, trastuzumabom in docetakselom, v primerjavi s 84,5 % pri bolnikih, ki so se zdravili s trastuzumabom in docetakselom, pri čemer se je nevtropenija stopnje 4 pojavila pri 50,9 % bolnikov, ki so se neoadjuvantno zdravili z zdravilom Perjeta, trastuzumabom in docetakselom in 60,2 % bolnikov, ki so se zdravili s trastuzumabom in docetakselom.
In the Nespo group, 83% were receiving dialysis and 17% were not receiving dialysis.
V skupini, ki je dobivala Nespo, je bilo 83 % bolnikov na dializi, 17 % pa ne.
In the new study, patients taking Combivir and those taking the two active substances separately had similar falls in viral load.
V novi študiji so imeli bolniki, ki so jemali zdravilo Combivir, in tisti, ki so učinkovini jemali ločeno, podobno znižanje virusne obremenitve.
In the newborn of a hepatitis B virus carrier-mother.
pri novorojencih, rojenih prenašalkam virusa hepatitisa B,
In the NHL phase 3 trial SABRINA (BO22334), local cutaneous reactions were reported in up to 20% of patients receiving subcutaneous MabThera.
V kliničnem preskušanju faze III SABRINA (BO22334) pri bolnikih z NHL je do 20 % bolnikov, ki so prejemali podkožno obliko zdravila MabThera, navedlo lokalne kožne reakcije.
In the non-controlled study C04-002 (SHEPHERD), PNH patients with at least one transfusion in the prior 24 months and at least 30,000 platelets/microliter received Soliris over a 52-week period.
V nekontrolirani študiji C04-002 (SHEPHERD) so bolniki s PNH, ki so prejeli najmanj eno transfuzijo v zadnjih 24 mesecih in najmanj 30.000 trombocitov na mikroliter, prejemali zdravilo Soliris 52 tednov.
In the non-diabetic studies including a mixed population of subjects with/without (treated) dyslipidemia, an increase in HDL-C and decrease in triglycerides (at one year) was observed.
V študijah nediabetičnih bolnikov, vključno z mešano populacijo preiskovancev z (zdravljeno) dislipidemijo ali brez nje, so (po enem letu) ugotovili zvišanje holesterola HDL in znižanje trigliceridov.
In the non-FL population the HR for IRC-assessed PFS was 0.94 [95% CI: 0.49, 1.90].
V populaciji, ki ni imela FL, je bilo razmerje ogroženosti po oceni IRC 0,94 [95-% interval zaupanja: 0,49; 1,90].
In the non-inferiority study, 1,429 acutely ill subjects (baseline mean PANSS total score: 85.7) who met DSM-IV criteria for schizophrenia were enrolled into the open-label phase and treated with
V študijo za oceno neinferiornosti so vključili 1.429 preiskovancev z akutno shizofrenijo s povprečno izhodiščno oceno 85,7 na celotni lestvici pozitivnih in negativnih sindromov (Positive and Negative Syndrome Scale, PANSS), ki so izpolnjevali merila za shizofrenijo po DSM-IV.
In the non-inferiority study, V59P6, immunogenicity was assessed among adolescents aged 11-17 years who had been randomised to receive either Menveo or ACWY-PS.
V študiji neinferiornosti, V59P6, so imunogenost ocenjevali v skupini mladostnikov, starih 11-17 let, ki so bili naključno razvrščeni bodisi za cepljenje s cepivom Menveo ali ACWY-PS.
In the non-squamous NSCLC study (CA209057), the safety profile in patients with baseline renal or hepatic impairment was comparable to that in the overall population.
V študiji pri neskvamoznem NSCLC (študija CA209057) je bil varnostni profil pri bolnikih z okvaro ledvic ali jeter v izhodišču primerljiv z varnostnim profilom v celotni populaciji.
In the offspring of rats given olanzapine, delays in fetal development and transient decreases in offspring activity levels were seen.
Pri potomcih podgan, ki so prejemale olanzapin, so opazili zastoje v fetalnem razvoju in prehodna znižanja v ravneh aktivnosti potomcev.
In the offspring of rats given olanzapine, delays in foetall development and transient decreases in offspring activity levels were seen.
Pri potomcih podgan, ki so prejemale olanzapin, so opazili zastoje v fetalnem razvoju in prehodna znižanja v ravneh aktivnosti potomcev.
In the OL LI phase all patients received 24 mg/m2 up to a maximum of 40 mg Humira every other week for 16 weeks.
V odprti uvajalni fazi so vsi bolniki 16 tednov dobivali 24 mg/m2 (do največ 40 mg) zdravila Humira vsak drugi teden.
In the OL LI phase all patients received 24 mg/m2 up to a maximum of 40 mg Humira every other week for 16 weeks.
V odprti uvajalni fazi so vsi bolniki 16 tednov dobivali 24 mg/m2 (do največ 40 mg) zdravilo Humira vsak drugi teden.
In the ongoing open label extension phase (Part II), the overall rate of infections remained similar at 306.6 per 100 patient years.
V odprti, podaljšani fazi, ki še poteka (faza II), je celokupen delež okužb ostal podoben in sicer 306,6 na 100 bolnik-let.
In the ongoing open label extension phase, decreases in neutrophil counts below 1 x 109/l, occurred in 15% of the tocilizumab group.
V odprti, podaljšani fazi, ki še poteka, se je zmanjšanje števila nevtrofilcev pod 1 x 109/l pojavilo pri 15 % v skupini, ki je prejemala tocilizumab.
In the ongoing open label extension phase, decreases in platelet counts below 100 x 103/µl, occurred in 3% of patients in the tocilizumab group, without associated bleeding events.
V odprti, podaljšani fazi, ki še poteka, se je zmanjšanje števila trombocitov pod 100 x 103/µl pojavilo pri 3 % bolnikov v skupini, ki je prejemala tocilizumab, brez sočasnih krvavitev.
In the ongoing open label extension phase, elevation in ALT or AST ≥ 3 x ULN occurred in 12% and 4% of patients, respectively, in the tocilizumab group.
V odprti, podaljšani fazi, ki še poteka, se je dvig ALT na ≥ 3-kratno ZMN pojavil pri 12 % bolnikov, dvig AST na ≥ 3-kratno ZMN pa pri 4 % bolnikov v skupini, ki je prejemala tocilizumab.
In the ongoing open label extension phase, the pattern and incidence of elevations in lipid parameters remained consistent with the 12 week controlled phase data.
V odprti, podaljšani fazi, ki še poteka, sta vzorec in incidenca dvigov parametrov lipidov ostala skladna s podatki 12-tedenske, kontrolirane faze.
In the open label follow-up phase, the treatment effect on CDMS was still evident after 3 and 5 years (Table 3), even though the majority of patients from the placebo-group was treated with Betaferon at least from the second year onwards.
V odprti fazi nadaljevanja študije so bili učinki zdravljenja na CDMS še vedno opazni po 3 in 5 letih (preglednica 3), čeprav je bila večina bolnikov iz skupine, ki je dobivala placebo, zdravljena z zdravilom Betaferon vsaj od drugega leta naprej.
In the open-label extension of RA Study III, the reduction in rate of progression of structural damage is maintained for 8 and 10 years in a subset of patients.
V odprtem podaljšanju študije revmatoidnega artritisa III, se upočasnitev napredovanja strukturne prizadetosti sklepov ohrani vseskozi 8 in 10 let v tej podskupini bolnikov.
In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomized to methotrexate monotherapy, Humira monotherapy and Humira/methotrexate combination therapy, respectively.
V odprtem podaljšanju študije revmatoidnega artritisa V je bila povprečna sprememba celotne Sharpove ocene v 10. letu pri bolnikih, ki so jih na začetku randomizirali na monoterapijo z metotreksatom, monoterapijo z zdravilom Humira in kombinacijo zdravila Humira/metotreksat, glede na izhodišče 10,8, 9,2 oz 3,9.
In the open-label extension of Studies I, II, III, and VI durable and sustained ACR 20, 50, and 70 responses have been observed through 7 years, 5 years, 5 years, and 2 years, respectively, of abatacept treatment.
Trajanje in ohranitev odzivov ACR 20, 50 in 70 so v odprtem podaljšku študije I spremljali 7 let zdravljenja z abataceptom, v odprtem podaljšku študije II 5 let zdravljenja z abataceptom, v odprtem podaljšku študije III 5 let zdravljenja z abataceptom in v odprtem podaljšku študije VI 2 leti zdravljenja z abataceptom.
In the open-label extension of Studies I, II, III, VI, and SC-I durable and sustained ACR 20, 50, and 70 responses have been observed through 7 years, 5 years, 5 years, 2 years, and 5 years, respectively, of abatacept treatment.
Trajanje in ohranitev odzivov ACR 20, 50 in 70 so v odprtem podaljšku študije I spremljali 7 let zdravljenja z abataceptom, v odprtem podaljšku študije II 5 let zdravljenja z abataceptom, v odprtem podaljšku študije III 5 let zdravljenja z abataceptom, v odprtem podaljšku študije VI 2 leti zdravljenja z abataceptom in v odprtem podaljšku študije SC-I 5 let zdravljenja z abataceptom.